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Development of disease is often due to deregulation of gene expression. The gene program is controlled at the 
post-transcriptional level by the action of small non-coding RNAs known as microRNAs (miRNAs), short, 
single-stranded molecules that control mRNA stability or translational repression via base pairing with regions 
in the 3' untranslated region of their target mRNAs. Over the last decade, considerable progress has been made 
to elucidate the roles of miRNAs in vascular pathogenesis and develop the use of miRNAs as innovative 
biomarkers in diagnostics, and as groundbreaking drugs in pharmacological treatments. It has been recently 
shown that several miRNAs are implicated in the course of chronic kidney disease (CKD) and are associated 
with vessel damage, such as vascular calcifications and atherosclerosis. The inflammatory miR-223 is increased 
in vitro in vascular smooth muscle cells subjected to uremic toxins and is also increased in vivo in more advanced 
stages of CKD. The endothelial-specific miR-126 is involved in vascular remodeling in response to laminar shear 
stress in HUVEC cells. Finally, miR-126 levels have been found to be deregulated in murine and human serum in 
the course of experimental CKD and in human diabetic patients. In conclusion, these miRNAs could play a role 
in CKD vascular remodeling and may therefore represent useful targets to prevent or treat complications of 
CKD. 
To cite this article: Metzinger-Le Meuth V, et al. miR-126 and miR-223 as biomarkers of vascular damage in the course of 
Chronic Kidney Disease. RNA Dis 2014; 1: e347. doi: 10.14800/rd.347. 
Introduction 
Patients with advanced stages of chronic kidney disease 
(CKD) exhibit higher cardiovascular morbidity and mortality, 
associated with the presence of cardiovascular diseases 
(CVD). CVD are the leading cause of mortality throughout the 
world. The World Health Organization has estimated that 17.3 
million people died from CVD in 2008, representing 30% of 
all global deaths. With aging of the population, the prevalence 
of CVD will inevitably increase to reach 23.3 million by 2030. 
Most CVD are caused by atherosclerosis, a pathological 
process that can affect any artery in the human body
[1]
. The
first phase of atherosclerosis, called intimal hyperplasia, starts 
with endothelial dysfunction and induction of smooth muscle 
cell migration and proliferation from the media to the intima, 
in turn leading to degeneration of the artery wall and local 
inflammation. All these phenomena are observed in the course 
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Due to the complexity of this process, it is generally 
considered that unconventional predictive factors will be 
increasingly useful for diagnosis. The understanding of the 
pathophysiological process of vascular calcifications has been 
substantially improved over the last decade, but further 




Since the turn of the millennium, microRNAs (miRNAs), 
a novel and abundant class of endogenous interfering RNAs, 
have become a new source of excitement in many fields of 
research in biology and medicine, as they have emerged as 
new promising biomarkers for numerous diseases. These 
small 20-24 nt non-coding RNAs fine-tune gene regulatory 
networks by affecting both the stability and translation of 
mRNAs in a post-transcriptional manner
[3]
. More than 1,500 
miRNAs have now been described, and are listed in 
dedicated databases. miRNA biogenesis starts with the 
transcription of a larger RNA product, Pri-miRNA. This 
transcription is usually performed by RNA polymerase II. 
Pri-miRNA, a few hundred to a few thousand nucleotide long 
transcript, is then cleaved in the nucleus by RNase III 
Drosha, with the aid of protein partner, DiGeorge syndrome 
critical region 8 (DGCR8). The resulting pre-miRNA hairpin 
(approx. 60 to 70 nt) migrates from the nucleus to the 
cytoplasm, where it is recognized and cleaved by Dicer 
RNase III. The resulting double-stranded RNA, known as the 
miRNA/miRNA* duplex, is unwound to single strands by 
the action of RNA-induced-silencing complex (RISC) that 
contains a further endonuclease, Argonaute 2 (Ago2). 
Finally, the RISC complex will bring the mature miRNA to 
target messenger RNAs, starting gene silencing
[3]
.  
In the mature miRNA, the 7 nt long seed sequence, 
usually located in nucleotides 2–8 of the miRNA, base-pairs 
with mammalian mRNAs by complementary base-pairing, 
mostly to the 3 prime Untranslated Region (3’UTR). 
However, several studies have shown that, in some cases, 
miRNAs bind the coding region or 5’UTR of respective 
target mRNAs
[4]
. Due to imperfect base-pairing outside of 
the seed region, hundreds of target mRNAs can likely bind to 
a single miRNA. This clearly illustrates the role of these 
small RNAs in the intricate network of gene regulation. 
Inversely, a single mRNA can be regulated by several 
miRNAs. Most researchers now estimate that the 1,500 
miRNAs identified to date regulate the expression of 
approximately 1/3 to 2/3 of all human genes
[4]
.  
The exact molecular mechanisms are still subject to 
controversy, between an action mostly involving inhibition 
of translation of target mRNAs, or induction of their 
degradation. According to Bartel’s team, in a vast majority of 
cases, mammalian microRNAs act by destabilizing their 





Recent data from the literature suggest that several 
microRNAs are involved in the pathophysiology of CKD
[6-9]
, 
since they are important regulators of vascular smooth 
muscle cell (VSMC) and endothelial cell plasticity. This 
review focuses on the known roles of miR-126 and miR-223 
in the endothelial cell phenotypic switch towards a 
deregulated state and the control of Vascular Smooth Muscle 
Cell (VSMC) transdifferentiation that occurs during vascular 
complications of CKD, illustrating that miRNAs are 
important modulators of vascular cell function in vascular 
disease. 
miR-126, an important modulator of endothelial cell 
dysfunction 
During blood vessel maturation, endothelial cells, that 
were motile and proliferative during vascular development, 
stabilize the endothelial lining, become quiescent, and 
generate a stable barrier between vascular tissue and blood. 
At that stage, endothelial cells act as sensors and respond to 
signals from the environment. During pathophysiological 
processes, such as tissue repair and the vascular pathogenesis 
observed in CKD, the endothelium will partially lose its 
cell-cell adhesion and intimal cells become mobile and 
proliferate. This process is called endothelial dysfunction
[10]
. 
Recent work has shown that microRNAs can modulate this 
phenotype switch (Figure 1A).  
For example, several recent studies have shown that 
endothelial miRNAs play important roles during vas-
culogenesis and in the response to inflammation and 
hemodynamic stress. The pro-angiogenic miR-126 is 
abundant in endothelial cells, plays an important role in 
vascular dysfunction and modulates the expression of 
Vascular Cell Adhesion Molecule-1 (VCAM-1)
[11-12]
 and 
chemokine Stromal cell-Derived Factor-1 
(SDF-1/CXCL-12)
[13-14]
. MiR-126 is one of the most 
abundant miRNAs in the endothelial cell, where it promotes 
the pro-angiogenic actions of VEGF and FGF and enhances 
blood vessel formation
[15]
. Interestingly, Zhaou et al. showed 
that endothelial miR-126 release is reduced by 
atheroprotective laminar shear stress
[16]
. Indeed, 
atherosclerosis occurs in arterial regions exposed to disturbed 
flow. Modifications of flow conditions have been shown to 
regulate expression of flow-sensitive miRNAs, known as 
mechano-miRs in endothelial cells both in vitro and in vivo, 
in turn regulating endothelial dysfunction and 
atherosclerosis. miR-126 has been implicated as one of these 
mechanosensitive athero-miRNAs
[17]
. However, the situation 
is more complex than it seems, as one miR-126 can mask the 
effect of another. miR-126 (also referred to as miR-126-3p)  
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Figure 1. miR-126 and mir-223 are biomarkers of Chronic Kidney Disease (CKD), atherosclerosis 
and vascular calcification. Synoptic representation of the relevance of miR-126 and miR-223, and 
specific mRNA targets in (A) a pictorial representation of the cell types present in normal and calcified 
aorta and (B) murine models of Chronic Kidney Disease (CKD), atherosclerosis and vascular 
calcification. In an inflammatory context in CKD, atherosclerosis and vascular calcification, contractile 
vascular smooth muscle cells (VSMCs) transdifferentiate into a synthetic phenotype, reflecting a 
pathogenic context, and endothelial cells become dysfunctional. 
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and miR-126* (also known as miR-126-5p) are highly 
expressed in the endothelium and have been shown to be 
differentially regulated by flow. miRNA* is generally 
considered to be degraded and therefore does not have any 
biological relevance. However, Schober surprisingly claimed 
that miR126* (-5p) is more highly expressed than miR-126 
in the endothelium and is the predominant atheroprotective 
regulator
[18]
. In this review, miR-126-3p is referred to as 
miR-126. 
We have previously observed endothelial dysfunction in 
our murine model of chronic kidney disease
[19]
, which is an 
indicator of subtle disturbances of endothelial function and 
which may potentially play an important role at this disease 
stage (Figure 1B). In vivo, we examined changes of miRNA 
expression in aortas of CKD and/or atherosclerotic mice and 
showed that miR-126 expression was markedly increased 
and expression of protein targets VCAM-1 and SDF-1 was 
altered during the course of CKD and/or atherosclerosis
[8]
. 
Even more marked changes were observed in mice 
developing both CKD and atherosclerosis, known to display 
vascular calcifications
[20]
. Finally, Sevelamer, a drug 
commonly used in CKD, partially corrected these changes in 
miR expression, suggesting a direct link between the 
observed miRNA alterations and uremic vascular toxicity. 
Mitchell et al.
[21]
 have demonstrated the presence of 
circulating miRNAs in human plasma. Circulating miRNAs 
are transported by micro vesicles, conferring the required 
stability and protection against RNase activity
[22]
 or in 
complexes with the chaperon Argonaute 2 and/or 
lipoproteins. Several studies have demonstrated a correlation 
between plasma miRNA and diseases such as cancer
[21]
, 
highlighting their roles as potential noninvasive 
biomarkers
[23]
. Stephanie Dimmeler’s team was the first to 
show that miRNA levels are altered in the serum of patients 
with coronary artery disease (CAD) compared to healthy 
counterparts. In cardiovascular disease studies, various 
endogenous circulating miRNAs (eg miR-454, U6 or 
miR-17-5p) were considered to normalize the levels of 
circulating miRNAs, but most people add a known amount of 
spiked-in exogenous non-human miRNA (eg synthetic 




Plasma levels of miR-126 had been shown to be decreased 
in type 2 diabetes
[25]
. We were the first to study miR-126 
expression in damaged vessels due to CKD. Our results 
established that miR-126 is decreased during the later stages 
of CKD in all pathological conditions. At the later stages of 
uremia, Apo-E KO mutation induced a decrease of serum 
miR-126 levels. On the other hand, CKD at this later stage of 
uremia triggered a decrease of miR-126. Interestingly, 
several miRNAs, including miR-126, have been shown to be 
secreted by endothelial cells, more precisely in blood 




It has been shown that administration of miR-126 rescued 
EC proliferation at predilection sites of limited 
atherosclerosis
[13]
. Systemic treatment of mice with 
microparticles after electric denudation of the endothelium 
accelerated re-endothelialization in vivo. Other experiments 
have revealed that micro particles released from apoptotic 
endothelial cells are integrated by neighbouring cells to 
promote EC migration and proliferation, two critical steps in 
endothelial repair
[26]
. miR-126 was the predominant miRNA 
in these microparticles. Microparticles derived from 
glucose-treated ECs contained fewer miR-126 and showed 
reduced endothelial repair capacity. This observation is 
particularly interesting, as the same authors reported that 
miR-126 is decreased in circulating microparticles from 






 also showed that microvesicles 
derived from endothelial progenitor cells are able to protect 
kidney cells (per tubular capillaries and tubular cells) in a rat 
model of acute kidney injury. Here again, miR-126 was 
found to be the main miRNA expressed in micro vesicles, in 
tandem with miR-296. The combined results of these studies 
strongly support the hypothesis that miR-126 promotes 
endothelial regeneration in vessels, but is also able to protect 
kidney tissue, and that increasing the production of this 
miRNA would be a potential therapeutic approach to limit 
the development of atherosclerosis and damage due to CKD 
and diabetes. 
miR-223 expression in smooth muscle and endothelial 
cells: a marker of inflammation? 
Unlike other muscle cells (skeletal and cardiac), VSMCs 
have an important plasticity enabling them to undergo a 
switch from a “synthetic” to a “contractile” phenotype, in 
response to physiological and pathological environmental 
signals. Growth factors, such as PDGF, or vascular damage 
induce VSMC dedifferentiation and consequently their 
transdifferentiation into migratory and proliferative 
(“synthetic”) cells. This phenotypic change is instrumental for 
angiogenesis and vascular repair, and is associated with 
significant changes in the VSMC gene expression pattern (ie 
an increase in the expression of VSMC-specific genes, such as 
calponin-1 (CNN), smooth muscle -actin (SMA) and SM22 
-actin (SM22). Two independent teams have highlighted the 
important role of miRNAs in VSMC development, 
differentiation, and pathophysiology after knocking out the 
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miRNA processing enzyme Dicer in murine VSMCs, which 
induced profound vascular abnormalities, resulting in 
embryonic lethality. Among miRNAs found to be expressed 
in the vasculature, miR-143 and miR-145 are the miRNAs 
most highly expressed in smooth muscle cells, and their 
down-regulation is directly associated with a phenotypic 




We have reported that miR-223 plays a significant role in 
vascular smooth muscle cell calcification  induced by 
inorganic phosphate (Pi), both in vitro
[9]
 and in vivo
[8] 
(Figure 
1A and B). Increased serum phosphate level has been 
recognized as a major risk factor in kidney disease and 
downstream vascular complications. Our data demonstrated 
the direct molecular and cellular effects of Pi on vascular 
smooth muscle cells, showing major impacts on calcification, 
proliferation and migration properties by modulating the 
expression of associated miRNAs and phenotypic marker 
genes. In our calcification models, we confirmed the 
previously described important roles of miR-143 and 
miR-145 on other normal and pathological cardiovascular 
events
[9]
. We also reported, for the first time, a similar role 
for miR-223, since this miRNA (first reported as an 
oncomiR, a marker of muscle damage and a key factor in 
osteoclast differentiation
[7]
) is expressed in VSMCs and is 
significantly upregulated in Pi-treated cells. Moreover, 
over-expressing miR-223 in VSMCs increased proliferation 
and markedly enhanced VSMC migration
[9]
. Our results 
therefore suggested that miR-223 is a potential biomarker of 
vascular calcification.  
In support of these in vitro findings, we also observed 
upregulation of miR-223 in aorta samples collected from 
experimental murine models of CKD and atherosclerosis, 
which display vascular calcification
[8]
. Moreover, the 
vascular expression of miR-223 is altered in these 
pathological conditions. Importantly, the levels of expression 
of miR-223 and its specific protein targets vary according to 
the stage of CKD. Finally, administration of the calcium-free 
phosphate binder, sevelamer carbonate, partially corrects 
miRNA deregulations, suggesting a possible direct link 
between the observed miRNA alterations and the vascular 
damage caused by CKD
[8]
.  
One of our study's most important findings was the 
up-regulation of miR-223 in aortas from both WT-CKD and 
Apo-E CKD mice with surgically induced CKD. Lu et al.
[29]
 
have already reported that miR-223 overexpression triggers 
the cellular uptake of glucose in cardiomyocytes by 
modulating GLUT-4 expression. We recently reported that 
miR-223 is expressed in VSMC and that this upregulation is 
a potential marker of VSMC damage
[9]
. Our present results 
further suggest that this is also true in vivo. miR-223 was 
initially considered to be not significantly expressed in 
endothelial cells in vitro
[25]
 (and our unpublished results). 
However, another team has recently shown that miR-223 is 
actually highly expressed in freshly isolated endothelial cells, 
but that miR-223 expression decreases very rapidly during 
routine cell subculture
[30]
. Interestingly, various transcription 
factors, such as vascular endothelial cell growth factor and 
basic fibroblast growth factor, further decreased miR-223 
expression. We also recently found miR-223 to be expressed 
in freshly isolated endothelial cells from the brain 
microvasculature
[31]
. It is therefore reasonable to postulate 
that miR-223 is present in both aortic cells from the media 
and endothelial cells from the intima. It is now widely 
recognized that chronic low-grade inflammation plays a key 
role in the initiation and propagation of CKD. Consequently, 
the marked increase in inflammatory miR-223 expression 
during the course of CKD and atherosclerosis in our 
experimental models is striking, and it would be interesting 
to determine whether this increase is beneficial (although 
insufficient to alleviate symptoms in the later stages of CKD) 
or detrimental.  
The essential question is how miR-223 can be transferred 
to vascular cells? Tabet et al.
[32]
 suggested that high-density 
lipoproteins (HDL) deliver functional microRNAs (miRNA) 
and showed that HDL delivers miR-223 to endothelial cells 
in order to suppress expression of intercellular adhesion 
molecule 1 (ICAM-1). This would be the first example of an 
extracellular miRNA regulating gene expression in cells in 
which it is not transcribed.  
Microvesicles such as exosomes from urine have also 
been demonstrated to contain miRNA
[33]
. The miRNA 
content in exosomes has been proposed to reflect the 
underlying pathophysiology of certain kidney diseases that 
obviously represent another new reservoir for biomarker 
discovery, but exosomes are also able to shuttle their cargo 
between kidney cells and change the recipient cell's proteome 
and function, partly by means of miR-126
[27]
.  
Altogether, the results discussed here provide new clues 
concerning the status of miRNA regulation during the course 
of CKD. MiRNAs are expressed in a cell- and tissue-specific 
manner, and have reshaped our view, even further increasing 
this complexity.  
In conclusion, we are now at a stage where miRNA 
expression can be studied in human CKD populations, before 
and after the vascular calcification stage, in order to develop 
miRNAs as new biomarkers, useful for diagnosis and 
treatment evaluation, but also to develop miRNAs as 
innovative targets for groundbreaking treatments (Figure 2). 
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